Northland Securities Comments on MiMedx Group Q1 Earnings

MiMedx Group, Inc (NASDAQ:MDXG) – Research analysts at Northland Securities issued their Q1 2026 earnings per share estimates for MiMedx Group in a research report issued on Thursday, February 26th. Northland Securities analyst C. Byrnes anticipates that the company will earn ($0.03) per share for the quarter. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Securities also issued estimates for MiMedx Group’s Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.04 EPS and FY2026 earnings at $0.04 EPS.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $118.10 million during the quarter, compared to analyst estimates of $106.78 million. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.

MDXG has been the topic of a number of other reports. Citizens Jmp initiated coverage on MiMedx Group in a research note on Monday, February 23rd. They issued a “market outperform” rating and a $10.00 price target on the stock. Lake Street Capital reduced their price target on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Cantor Fitzgerald dropped their target price on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Wall Street Zen downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Mizuho lowered their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 17th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, MiMedx Group presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.60.

MiMedx Group Stock Down 1.0%

Shares of NASDAQ:MDXG opened at $4.89 on Monday. MiMedx Group has a fifty-two week low of $4.78 and a fifty-two week high of $8.46. The firm’s 50 day moving average price is $5.70 and its 200 day moving average price is $6.57. The stock has a market cap of $726.51 million, a price-to-earnings ratio of 15.28 and a beta of 1.60. The company has a quick ratio of 3.92, a current ratio of 4.32 and a debt-to-equity ratio of 0.06.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Trigran Investments Inc. raised its position in MiMedx Group by 10.4% during the second quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock worth $51,266,000 after acquiring an additional 790,901 shares during the last quarter. Vanguard Group Inc. raised its position in shares of MiMedx Group by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock worth $48,637,000 after buying an additional 382,623 shares during the period. State Street Corp raised its holdings in shares of MiMedx Group by 6.1% in the 4th quarter. State Street Corp now owns 3,813,796 shares of the company’s stock worth $25,819,000 after purchasing an additional 219,190 shares during the period. First Light Asset Management LLC lifted its position in MiMedx Group by 89.5% during the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock valued at $25,498,000 after buying an additional 1,725,458 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of MiMedx Group by 4.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,479,369 shares of the company’s stock valued at $16,786,000 after acquiring an additional 97,036 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.